Hematology diagnostics market seen reaching $8.71B by 2035

The global hematology diagnostics market is projected to grow from $4.81 billion in 2026 to $8.71 billion by 2035, according to Market Research Future. The report points to automation, AI-enabled digital morphology and point-of-care testing as the main forces reshaping how hospitals and labs handle blood testing.

Why it matters: - The market is moving toward faster, more automated blood testing as laboratories face staffing shortages and rising test volume. - Growth in diabetes and cancer-related testing is expanding recurring demand for hematology instruments, consumables and software. - The shift affects hospital labs, reference labs and point-of-care settings that rely on quicker turnaround and standardized results.

What happened: - Market Research Future said the global hematology diagnostics market is expected to rise from $4.81 billion in 2026 to $8.71 billion by 2035. - The forecast implies a 7.16% compound annual growth rate during 2026-2035. - The market base was estimated at $4.49 billion in 2025. - The report ties demand to laboratory automation, AI-enabled digital morphology and decentralized testing. - A free sample is available here.

The details: - Persistent shortages of trained medical laboratory scientists are pushing hospitals and labs toward automated analyzers and integrated workflow platforms. - Laboratories are replacing manual differential workflows and standalone 3-part counters with integrated 5/6-part analyzers linked to digital morphology and laboratory information systems. - The report says AI-assisted slide review is reducing reliance on skilled technologists while routine specimens are handled with minimal human touch. - Artificial intelligence can pre-classify abnormal cells and flag specimens for pathologist review in minutes. - Sysmex and Beckman Coulter are among the platforms cited for digital image analysis of blood smears and abnormal-cell detection. - McKinsey estimates AI-augmented laboratory operations could cut manual slide review workload by 30%-40% across the diagnostic value chain. - The report identifies services and software as the fastest-growing product segment at 11.40% CAGR through 2035. - Point-of-care settings are forecast to expand at an 11.65% CAGR through 2035. - Complete blood count testing remains the dominant test type with about 38.9% share in 2024. - HbA1c and specialized tests are projected to be the fastest-growing test type at 10.30% CAGR. - Hospital laboratories held the largest end-user share at about 43.1% in 2024. - Independent and reference labs generated $1.34 billion in 2024. - Academic and research institutes accounted for $0.38 billion in 2025. - North America held about 31% of the market in 2025. - Europe was the second-largest region at $1.21 billion in 2025. - Asia-Pacific was the fastest-growing region at 8.18% CAGR and represented $1.19 billion in 2025. - South America reached $0.40 billion in 2025. - The Middle East and Africa reached $0.29 billion in 2025. - The report estimates the market has medium concentration, with the top five vendors holding roughly 62%-68% of global revenue. - Sysmex, Beckman Coulter, Abbott Laboratories, Siemens Healthineers, HORIBA Medical and Mindray are named among leading companies. - Read the detailed report.

Between the lines: - The report suggests hematology is becoming less of a manual lab discipline and more of a connected automation market. - Vendor competition is shifting toward throughput, workflow integration and subscription-based services instead of price alone. - High switching costs can make installed platforms sticky once labs standardize reagents, training and connectivity. - The forecast implies that AI and automation could matter as much as test demand in driving revenue growth.

What’s next: - The report expects AI-driven autonomous lab operations to handle more than 60% of routine hematology specimens in leading markets by 2030. - Revenue growth is expected to tilt further toward consumables and connected services over instrument sales. - The report also projects decentralized clinical trials could represent 40% of Phase II/III precision hematology trials by 2028. - Molecular methods and digital morphology are expected to converge on unified platforms over the next decade.

The bottom line: - Hematology diagnostics is moving toward a more automated, software-connected market where recurring test volume, AI and workflow efficiency drive growth as much as the instruments themselves.